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Discovery of common and rare genetic risk 
variants for colorectal cancer
To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases 
and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-
wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an 
additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a 
combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10−8, bringing the number 
of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog 
signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability 
analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will 
improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.
Colorectal cancer (CRC) is the fourth leading cancer-related cause of death worldwide1 and presents a major public health burden. Up to 35% of interindividual variability in CRC risk 
has been attributed to genetic factors2,3. Family-based studies have 
identified rare high-penetrance mutations in at least a dozen genes, 
but collectively, these account for only a small fraction of famil-
ial risk4. Over the past decade, genome-wide association studies 
(GWASs) for sporadic CRC, which constitutes the majority of cases, 
have identified ~60 association signals at over 50 loci5–22. Yet most 
of the genetic factors contributing to CRC risk remain undefined. 
This severely hampers our understanding of biological processes 
underlying CRC. It also limits CRC precision prevention, including 
individualized preventive screening recommendations and devel-
opment of cancer prevention drugs. The contribution of rare varia-
tion to sporadic CRC is particularly poorly understood.
To expand the catalog of CRC risk loci and improve our under-
standing of rare variants, genes and pathways influencing spo-
radic CRC risk and risk prediction, we performed the largest and 
most comprehensive whole-genome sequencing (WGS) study and 
GWAS meta-analysis for CRC so far, combining data from three 
consortia: the Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO), the Colorectal Cancer Transdisciplinary 
Study (CORECT) and the Colon Cancer Family Registry (CCFR). 
Our study almost doubles the number of individuals analyzed, 
incorporating GWAS results from > 125,000 individuals, and sub-
stantially expands and strengthens our understanding of biological 
processes underlying CRC risk.
Results
Study overview. We performed WGS of 1,439 CRC cases and 720 
controls of European ancestry at low sequencing depth (3.8–8.6× ). 
We detected, called and estimated haplotype phase for 31.8 mil-
lion genetic variants, including 1.7 million short insertion-deletion 
variants (indels) (Methods). These data include many rare variants 
not studied by GWAS. As other large-scale WGS studies have used 
a similar design, we expected to have near-complete ascertain-
ment of single-nucleotide variants with minor allele count (MAC) 
> 5 (minor allele frequency (MAF) > 0.1%), and high accuracy at 
heterozygous genotypes23,24. We tested 14.4 million variants with 
MAC ≥ 5 for CRC association using logistic regression (Methods) 
but did not find any significant associations. To increase power to 
detect associations with rare and low-frequency variants of mod-
est effect, we imputed variants from the sequencing experiment 
into 34,869 cases and 29,051 controls of predominantly European 
(91.7%) and East Asian ancestry (8.3%) from 30 existing GWASs 
(Methods and Supplementary Table 1). By design, two-thirds of 
sequenced individuals were CRC cases, thereby enriching the panel 
for rare or low-frequency alleles that increase CRC risk. We contrib-
uted our sequencing data to the Haplotype Reference Consortium 
(HRC)25 and imputed the 30 existing GWASs to the HRC panel, 
which comprises haplotypes for 32,488 individuals. Results of 
these GWAS meta-analyses (referred to as stage 1 meta-analysis; 
Methods) informed the design of a custom Illumina array compris-
ing the OncoArray, a custom array to identify cancer risk loci26, and 
15,802 additional variants selected based on stage 1 meta-analysis 
results. We genotyped 12,007 cases and 12,000 controls of European 
ancestry with this custom array, and combined them with an addi-
tional 11,255 cases and 26,296 controls with GWAS data, resulting 
in a stage 2 meta-analysis of 23,262 CRC cases and 38,296 controls 
(Methods, Supplementary Fig. 1 and Supplementary Table 1). Next, 
we performed a combined (stage 1 + stage 2) meta-analysis of up 
to 58,131 cases and 67,347 controls. This meta-analysis was based 
on the HRC panel–imputed data because, given its large size, this 
panel results in superior imputation quality and enables accurate 
imputation of variants with MAFs as low as 0.1% (ref. 25). Here, 
we report new association signals discovered through our custom 
genotyping experiment and replicated in stage 2 at the Bonferroni 
significance threshold of P < 7.8 × 10−6 (Methods), as well as dis-
tinct association signals passing the genome-wide significance 
(GWS) threshold of P < 5 × 10−8 in the combined meta-analysis of 
up to 125,478 individuals.
Colorectal cancer risk loci. In the combined meta-analysis, we 
identified 30 new CRC risk loci reaching GWS and > 500 kilobases 
(kb) away from previously reported CRC risk variants (Table 1 and 
Supplementary Figs. 2 and 3). Some 22 of these were represented on 
our custom genotyping panel, either by the lead variant (15 loci) or 
by a variant in linkage disequilibrium (LD) (7 loci; r2 > 0.7). Of these 
22 variants, eight attained the Bonferroni significance threshold in 
the stage 2 meta-analysis (Table 1).
Among these eight loci is the first rare variant signal identi-
fied for sporadic CRC, involving five 0.3% frequency variants at 
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5q21.1, near genes CHD1 and RGMB. SNP rs145364999, which is 
intronic to CHD1, had high-quality genotyping (Supplementary 
Fig. 4). The variant was well imputed in the remaining sample 
sets (imputation quality r2 of 0.66–0.87; Supplementary Table 2) 
and there was no evidence of heterogeneity of effects (heteroge-
neity P = 0.63; Supplementary Table 2). The rare allele confers a 
strong protective effect (allelic odds ratio (OR) = 0.52 in stage 2; 
95% confidence interval (CI) = 0.40–0.68). Chromatin remodel-
ing factor CHD1 provides an especially plausible candidate and 
is a synthetically essential gene27 that is occasionally deleted in 
some cancers, but always retained in PTEN-deficient cancers28. 
The resulting mutually exclusive deletion pattern of CHD1 and 
PTEN has been observed in prostate, breast and CRC The Cancer 
Genome Atlas data28. We hypothesize that the rare allele confers a 
protective effect by lowering CHD1 expression, which is required 
for nuclear factor–κ β (NF-κ β ) pathway activation and growth in 
cancer cells driven by loss of the tumor suppressor gene PTEN28. 
However, we cannot rule out involvement of nearby candidate 
gene RGMB that encodes a co-receptor for bone morphogenetic 
proteins BMP2 and BMP4, both of which are linked to CRC risk 
through GWAS9,11. Additionally, RGMB binds to PD-L2 (ref. 29), a 
known ligand of PD-1, an immune checkpoint blockade receptor 
targeted by cancer immunotherapy30.
The vast majority of new association signals involve common 
variants. We found associations near strong candidate genes for 
CRC risk in pathways or gene families not previously implicated by 
GWAS. Locus 13q22.1, represented by lead SNP rs78341008 (MAF 
7.2%; P = 3.2 × 10−10), is near KLF5, a known CRC oncogene that 
can be activated by somatic hotspot mutations or super-enhancer 
duplications31,32. KLF5 encodes transcription factor Krüppel-like 
factor 5 (KLF5), which promotes cell proliferation and is highly 
expressed in intestinal crypt stem cells. We also found an associa-
tion at locus 19p13.11, near KLF2. KLF2 expression in endothelial 
cells is critical for normal blood vessel function33,34. Downregulated 
KLF2 expression in colon tumor tissues contributes to structurally 
and functionally abnormal tumor blood vessels, leading to impaired 
blood flow and hypoxia in tumors35. Another locus at 9q31.1 is near 
LPAR1, which encodes a receptor for lysophosphatidic acid (LPA). 
LPA-induced expression of hypoxia-inducible factor 1 (HIF-1α ), a 
key regulator of cellular adaptation to hypoxia and tumorigenesis, 
depends on KLF5 (ref. 36). Additionally, LPA activates multiple sig-
naling pathways and stimulates proliferation of colon cancer cells by 
activation of KLF5 (ref. 37). Another locus (7p13) is near SNHG15, 
which encodes a long noncoding RNA (lncRNA) that epigenetically 
represses KLF2 to promote pancreatic cancer proliferation38.
We found two loci near members of the Hedgehog (Hh) signal-
ing pathway. Aberrant activation of this pathway, caused by somatic 
mutations or changes in expression, can drive tumorigenesis in many 
tumors39. Notably, downregulated stromal cell Hh signaling acceler-
ates colonic tumorigenesis in mice40. Locus 3q13.2, represented by 
low-frequency lead SNP rs72942485 (MAF 2.2%; P = 2.1 × 10−8), 
overlaps with BOC, which encodes a Hh coreceptor molecule. In 
medulloblastoma, upregulated BOC promotes Hh-driven tumor 
progression through cyclin D1–induced DNA damage41. In pancre-
atic cancer, a complex role for stromal BOC expression in tumori-
genesis and angiogenesis has been reported42. Locus 4q31.21 is near 
HHIP, which encodes an inhibitor of Hh signaling. Notably, the Hh 
signaling pathway was also significantly enriched in our pathway 
analysis (described below).
Locus 11q22.1 is near YAP1, which encodes a critical down-
stream regulatory target in the Hippo signaling pathway that is 
gaining recognition as a pivotal player in organ size control and 
tumorigenesis43. YAP1 is highly expressed in intestinal crypt stem 
cells, and in transgenic mice, its overexpression led to severe intes-
tinal dysplasia and loss of differentiated cell types44, reminiscent of 
phenotypes observed in mice and humans with deleterious germline 
 APC mutations. Further, hypoxia-inducible factor 2α (HIF-2α ) 
promotes colon cancer growth by upregulating YAP1 activity45.
We provide further evidence for a link between immune func-
tion and CRC pathogenesis, and implicate the major histocom-
patibility complex (MHC) in CRC risk. We identified a locus near 
genes HLA-DRB1 and HLA-DQA1 that is associated with immune-
mediated diseases46.
We identified two new loci near known tumor suppressor genes. 
Locus 4q24 is near TET2, a chromatin-remodeling gene that is fre-
quently somatically mutated in multiple cancers, including colon 
cancer47, and that overlaps with GWAS signals for multiple other 
cancers48–50. The CDKN2B-CDKN2A-ANRIL (CDKN2B-AS1) locus 
at 9p21.3 is a well-established hotspot of pleiotropic GWAS asso-
ciations for many complex diseases, including coronary artery 
disease51, type 2 diabetes52 and cancers50,53–56. Notably, lead variant 
rs1537372 is in high LD (r2 = 0.82) with variants associated with 
coronary artery disease51 and endometriosis57, but not with the 
other cancer-associated variants. CDKN2A and CDKN2B encode 
cyclin-dependent kinase (CDK) inhibitors that regulate the cell 
cycle. CDKN2A is one of the most commonly inactivated genes in 
cancer, and is a high penetrance gene for melanoma58,59. CDKN2B 
activation is tightly controlled by the cytokine TGF-β , further link-
ing this signaling pathway with CRC tumorigenesis60.
Our findings implicate genes in pathways with established roles 
in CRC pathogenesis. We identified loci at SMAD3 and SMAD9, 
members of the TGF-β signaling pathway, which includes genes 
linked to familial CRC syndromes (for example, SMAD4 and 
BMPR1A) and several GWAS-implicated genes (for example, 
SMAD7, BMP2 and BMP4)61. We identified another locus near 
TGF-β receptor 1 (TGFBR1). Nearby gene GALNT12 harbors 
inactivating germline and somatic mutations in human colon can-
cers62 and therefore could also be the regulated effector gene. We 
identified a locus at 14q23.1 near DACT1, a member of the Wnt- 
β -catenin pathway which includes genes previously linked to famil-
ial CRC syndromes (APC63), and several GWAS-implicated genes 
(for example, CTNNB118 and TCF7L217). Genes related to telomere 
biology were linked by other GWASs: TERC10 and TERT22, which 
encode the RNA and protein subunits of telomerase, respectively, 
and FEN1 (ref. 17), which is involved in telomere stability64. A new 
locus at 20q13.33 harbors another gene related to telomere biology, 
RTEL1. This gene is involved in DNA double-strand-break repair, 
and overlaps with GWAS signals for cancers55,65 and inflammation-
related phenotypes, including inflammatory bowel disease66 and 
atopic dermatitis67.
Of 61 signals at 56 loci previously associated with CRC at 
GWS, 42 showed association evidence at P < 5 × 10−8 in the com-
bined meta-analysis, and 55 at P < 0.05 in the independent stage 2 
meta-analysis (Supplementary Table 3). Notably, the association of 
rs755229494 at locus 5q22.2 (P = 2.1 × 10−12) was driven by studies 
of predominantly subjects with Ashkenazi Jewish ancestry, and this 
SNP is in perfect LD with known missense SNP rs1801155 in the 
APC gene (p.Ile1307Lys), the minor allele of which is enriched in 
this population (MAF 6%), but rare in other populations68,69.
Delineating distinct association signals at CRC risk loci. To iden-
tify additional independent association signals at known or new 
CRC risk loci, we conducted conditional analysis using individ-
ual-level data of 125,478 participants (Methods). At nine loci, we 
observed ten new independent association signals that attained a 
P value in a joint multiple-variant analysis (PJ) < 5 × 10−8 (Table 2, 
Supplementary Table 4 and Supplementary Fig. 5). Because this 
analysis focused on < 5% of the genome, we also report signals at 
PJ < 1 × 10−5 in Supplementary Table 5. At 22 loci, we observed 25 
new suggestive associations with PJ < 1 × 10−5.
At locus 11q13.4, near POLD3 and CHRDL2, we identified a 
new low-frequency variant (lead SNP rs61389091, MAF 3.94%) 
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stage 1 meta-analysis: up 
to 34,869 cases and 29,051 
controls
stage 2 meta-analysis: up 
to 23,262 cases and 38,296 
controls
combined meta-analysis: up 
to 58,131 cases and 67,347 
controls
OR 95% ci P OR 95% ci P OR 95% ci P
Rare variants
 5q21.1 RGMB; CHD1 rs145364999a 5 98,206,082 T/A 99.69 1.57 1.20–2.05 9.0 × 10−4 1.93 1.48–2.52 1.0 × 10−6 1.74 1.45–2.10 6.3 × 10−9
Low-frequency variants
 3q13.2 BOC rs72942485 3 112,999,560 G/A 98.02 1.16 1.07–1.26 2.5 × 10−4 1.23 1.12–1.35 1.5 × 10−5 1.19 1.12–1.26 2.1 × 10−8
Common variants
 1p34.3 FHL3 rs4360494b 1 38,455,891 G/C 45.39 1.05 1.03–1.08 2.9 × 10−5 1.06 1.03–1.08 3.3 × 10−5 1.05 1.04–1.07 3.8 × 10−9
 1p32.3 TTC22; 
PCSK9
rs12144319a 1 55,246,035 C/T 25.48 1.07 1.04–1.10 1.4 × 10−6 1.07 1.04–1.10 5.5 × 10−6 1.07 1.05–1.09 3.3 × 10−11
 2q24.2 MARCH7; 
TANC1
rs448513b 2 159,964,552 C/T 32.60 1.06 1.03–1.08 1.9 × 10−5 1.05 1.02–1.08 5.8 × 10−4 1.05 1.03–1.07 4.4 × 10−8
 2q33.1 SATB2 rs983402a 2 199,781,586 T/C 33.12 1.05 1.03–1.08 7.2 × 10−5 1.08 1.05–1.11 1.0 × 10−8 1.07 1.05–1.09 7.7 × 10−12
 3q22.2 SLCO2A1 rs10049390b 3 133,701,119 A/G 73.53 1.06 1.03–1.09 4.9 × 10−5 1.07 1.04–1.10 1.8 × 10−5 1.06 1.04–1.08 3.8 × 10−9
 4q24 TET2 rs1391441 4 106,128,760 A/G 67.20 1.05 1.02–1.07 1.5 × 10−4 1.06 1.03–1.09 2.3 × 10−5 1.05 1.03–1.07 1.6 × 10−8
 4q31.21 HHIP rs11727676 4 145,659,064 C/T 9.80 1.08 1.03–1.13 4.5 × 10−4 1.10 1.05–1.14 1.5 × 10−5 1.09 1.06–1.12 2.9 × 10−8
 6p21.32 HLA-DRB1; 
HLA-DQA1
rs9271695a 6 32,593,080 G/A 79.54 1.09 1.06–1.13 1.3 × 10−7 1.09 1.05–1.12 1.7 × 10−7 1.09 1.07–1.12 1.1 × 10−13




rs12672022b 7 45,136,423 T/C 83.45 1.07 1.04-1.11 1.6 × 10−5 1.06 1.03-1.10 4.4× 10−4 1.07 1.04-1.09 2.8× 10−8
 9p21.3 ANRIL; 
CDKN2A; 
CDKN2B
rs1537372b 9 22,103,183 G/T 56.92 1.05 1.02–1.07 1.4 × 10−4 1.06 1.03–1.08 2.4 × 10−5 1.05 1.03–1.07 1.4 × 10−8
 9q22.33 GALNT12; 
TGFBR1
rs34405347b 9 101,679,752 T/G 90.34 1.08 1.04–1.13 5.5 × 10−5 1.09 1.04–1.13 1.5 × 10−4 1.09 1.05–1.12 3.1 × 10−8
 9q31.3 LPAR1 rs10980628 9 113,671,403 C/T 21.06 1.05 1.02–1.09 3.1 × 10−4 1.08 1.05–1.11 1.3 × 10−6 1.07 1.04–1.09 2.8 × 10−9
 11q22.1 YAP1 rs2186607 11 101,656,397 T/A 51.78 1.05 1.03–1.08 1.1 × 10−5 1.05 1.03–1.08 3.3 × 10−5 1.05 1.04–1.07 1.5 × 10−9
 12q12 PRICKLE1; 
YAF2
rs11610543b 12 43,134,191 G/A 50.13 1.05 1.03–1.08 1.1 × 10−5 1.06 1.03–1.08 2.8 × 10−5 1.05 1.04–1.07 1.3 × 10−9
12q13.3 STAT6; LRP1; 
NAB2
rs4759277 12 57,533,690 A/C 35.46 1.07 1.04–1.09 8.4 × 10−7 1.04 1.02–1.07 1.6 × 10−3 1.05 1.04–1.07 9.4 × 10−9
 13q13.3 SMAD9 rs7333607a 13 37,462,010 G/A 23.50 1.09 1.06–1.12 2.5 × 10−8 1.07 1.04–1.10 4.4 × 10−6 1.08 1.06–1.10 6.3 × 10−13
 13q22.1 KLF5 rs78341008b 13 73,791,554 C/T 7.19 1.13 1.07–1.18 1.4 × 10−6 1.11 1.05–1.16 4.8 × 10−5 1.12 1.08–1.16 3.2 × 10−10
 13q34 COL4A2; 
COL4A1; 
RAB20
rs8000189 13 111,075,881 T/C 64.01 1.05 1.02–1.07 2.1 × 10−4 1.07 1.04–1.10 1.3 × 10−6 1.06 1.04–1.08 1.8 × 10−9
 14q23.1 DACT1 rs17094983b 14 59,189,361 G/A 87.73 1.10 1.07–1.15 8.4 × 10−8 1.08 1.04–1.12 9.0 × 10−5 1.09 1.06–1.12 4.6 × 10−11
 15q22.33 SMAD3 rs56324967a 15 67,402,824 C/T 67.57 1.07 1.04–1.10 2.2 × 10−7 1.08 1.05–1.11 9.8 × 10−8 1.07 1.05–1.09 1.1 × 10−13
 16q23.2 MAF rs9930005b 16 80,043,258 C/A 43.03 1.05 1.03–1.08 1.3 × 10−5 1.05 1.02–1.07 4.0 × 10−4 1.05 1.03–1.07 2.1 × 10−8
 17p12 LINC00675 rs1078643a 17 10,707,241 A/G 76.36 1.07 1.04–1.10 9.2 × 10−6 1.09 1.05–1.12 1.1 × 10−7 1.08 1.05–1.10 6.6 × 10−12
 17q24.3 LINC00673 rs983318b 17 70,413,253 A/G 25.26 1.07 1.04–1.10 1.2 × 10−6 1.05 1.02-1.08 8.0 × 10−4 1.06 1.04–1.08 5.6 × 10−9
 17q25.3 RAB40B; 
METRNL
rs75954926a 17 81,061,048 G/A 65.68 1.10 1.07–1.13 9.4 × 10−11 1.09 1.06-1.12 4.8 × 10−9 1.09 1.07–1.11 3.0 × 10−18
 19p13.11 KLF2 rs34797592b 19 16,417,198 T/C 11.82 1.09 1.05–1.13 8.2 × 10−6 1.09 1.05–1.13 1.2 × 10−5 1.09 1.06–1.12 4.2 × 10−10
 19q13.43 TRIM28 rs73068325 19 59,079,096 T/C 18.26 1.06 1.03–1.09 2.1 × 10−4 1.07 1.04–1.11 5.0 × 10−5 1.07 1.04–1.09 4.2 × 10−8
 20q13.12 TOX2; HNF4A rs6031311b 20 42,666,475 T/C 75.91 1.07 1.04–1.10 1.7 × 10−6 1.05 1.02–1.08 7.6 × 10−4 1.06 1.04–1.08 6.8 × 10−9
 20q13.33 TNFRSF6B; 
RTEL1
rs2738783b,c 20 62,308,612 T/G 20.29 1.07 1.04–1.10 2.6 × 10−6 1.05 1.02–1.08 3.3 × 10−3 1.06 1.04–1.08 5.3 × 10−8
Lead variant is the most associated variant at the locus. Reference SNP cluster ID (rsID) based on NCBI dbSNP Build 150. Alleles are on the +  strand. Chr., chromosome; RAF, risk allele frequency, based on 
stage 2 data; OR, odds ratio estimate for the risk allele. All P values reported in this table are based on fixed-effects inverse variance–weighted meta-analysis. aVariant or LD proxy (r2 >  0.7) was selected 
for our custom genotyping panel and formally replicates in the stage 2 meta-analysis at a Bonferroni significance threshold of P <  7.8 ×  10-6. bVariant or LD proxy (r2 >  0.7) was selected for our custom 
genotyping panel but did not attain Bonferroni significance in the stage 2 meta-analysis. cThis SNP reached genome-wide significance in the combined (stage 1 +  stage 2) sample-size weighted meta-
analysis based on likelihood-ratio test results (P =  4.9 ×  10−8).
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separated by a recombination hotspot from the known common 
variant signal12 (LD r2 between lead SNPs < 0.01). At 5p15.33, we 
identified another lower-frequency variant association (lead SNP 
rs78368589, MAF 5.97%), which was independent from the previ-
ously reported common variant signal 56 kb away, near TERT and 
CLPTM1L (LD r2 with lead SNP rs2735940 < 0.01)22. Variants in this 
region were linked to many cancer types, including lung, prostate, 
breast and ovarian cancer70.
The remaining eight new signals involved common variants. At 
new locus 2q33.1, near genes PLCL1 and SATB2, two statistically 
independent associations (LD r2 between two lead SNPs < 0.01) are 
separated by a recombination hotspot (Supplementary Fig. 5). In 
the MHC region, we identified a conditionally independent signal 
near genes involved in NF-κ β signaling, including the gene encod-
ing tumor necrosis factor-α , genes for the stress-signaling proteins 
MICA and MICB, and HLA-B. Locus 20p12.3, near BMP2, har-
bored four distinct association signals (Fig. 1), two of which have 
been reported10,11 (Supplementary Table 5). All four SNPs selected 
in the model were in pairwise linkage equilibrium (maximum 
LD r2 = 0.039, between rs189583 and rs994308). Our conditional 
analysis further confirmed that the signal ~1-Mb centromeric of 
BMP2, near gene HAO1, is independent. At locus 8q24.21 near 
MYC, the locus showing the second strongest statistical evidence 
of association in the combined meta-analysis (lead SNP rs6983267; 
P = 3.4 × 10−64), we identified a second independent signal (lead 
SNP rs4313119, PJ = 2.1 × 10−9; LD r2 with rs6983267 < 0.001). At 
the recently reported locus 5p13.1 (ref. 22), near the noncoding 
RNA gene LINC00603, we identified an additional signal (lead 
SNP rs7708610) that was partly masked by the reported signal in 
the single-variant analysis due to the negative correlation between 
rs7708610 and rs12514517 (r = − 0.18; r2 = 0.03). This caused sig-
nificance for both SNPs to increase markedly when fitted jointly 
(rs7708610, unconditional P = 1.5 × 10−5 and PJ = 3.8 × 10−9). At 
locus 12p13.32 near CCND2, we identified a new signal (lead SNP 
rs3217874, PJ = 2.4 × 10−9) and confirmed two previously associated 
signals13–15 (Supplementary Note). At the GREM1 locus on 15q13.3, 
two independent signals have been described11. Our analyses sug-
gest that this locus harbors three signals. A new signal represented 
by SNP rs17816465 is conditionally independent from the other two 
signals (PJ = 1.4 × 10−10, conditioned on rs2293581 and rs12708491; 
LD with conditioning SNPs r2 < 0.01; Supplementary Note).
Additionally, signals with PJ values approaching GWS were 
observed at new locus 3q13.2 near BOC (rs13086367, uncondi-
tional P = 6.7 × 10−8, PJ = 6.9 × 10−8, MAF = 47.4%), 96 kb from the 
low-frequency signal represented by rs72942485 (unconditional 
P = 2.1 × 10−8, PJ = 1.3 × 10−8, MAF = 2.2%); at known locus 10q22.3 
near ZMIZ1 (rs1250567, unconditional P = 3.1 × 10−8, PJ = 7.2 × 10−8, 
MAF = 45.1%); and at new locus 13q22.1 near KLF5 (rs45597035, 
unconditional P = 2.7 × 10−9, PJ = 8.1 × 10−8, MAF = 34.4%) 
(Supplementary Table 5). Furthermore, we clarified previously 
reported independent association signals (Supplementary Note).
Associations of CRC risk variants with other traits. Some 19 of 
the GWS association signals for CRC were in high LD (r2 > 0.7) 
Table 2 | additional new conditionally independent association signals at known and newly identified cRc risk loci that reach 












ORunconditional 95% ci Punconditional Joint multiple-variant analysis
conditioning 
variant(s)
ORconditional 95% ci Pconditional
Low-frequency variants
 11q13.4 POLD3 rs61389091 11 74,427,921 C/T 96.06 1.23 1.18–1.29 1.2 × 10−18 rs7121958a, 
rs7946853
1.21 1.16–1.27 3.7 × 10−16
Common variants
 2q33.1 SATB2 rs11884596 2 199,612,407 C/T 38.23 1.06 1.04–1.08 1.1 × 10−9 rs983402 1.06 1.04–1.07 3.6 × 10−9
 5p15.33 TERT; 
CLPTM1L
rs78368589 5 1,240,204 T/C 5.97 1.14 1.10–1.18 9.4 × 10−12 rs2735940a 1.12 1.08–1.16 4.1 × 10−9
 5p13.1 LINC00603; 
PTGER4
rs7708610 5 40,102,443 A/G 35.64 1.04 1.02–1.06 1.5 × 10−5 rs12514517a 1.06 1.04–1.08 3.8 × 10−9
 6p21.32 HLA-B; 
MICA; MICB; 
NFKBIL1; TNF
rs2516420 6 31,449,620 C/T 92.63 1.10 1.06–1.13 1.3 × 10−7 rs9271695, 
rs116685461, 
rs116353863
1.12 1.08–1.16 2.0 × 10−10
 8q24.21 MYC rs4313119 8 128,571,855 G/T 74.86 1.06 1.04–1.08 1.0 × 10−9 rs6983267a, 
rs7013278
1.06 1.04–1.08 2.1 × 10−9
 12p13.32 CCND2 rs3217874 12 4,400,808 T/C 42.82 1.08 1.06–1.10 1.2 × 10−17 rs3217810a, 
rs35808169a
1.06 1.04–1.08 2.4 × 10−9
 15q13.3 GREM1 rs17816465 15 33,156,386 A/G 20.55 1.07 1.04–1.09 6.8 × 10−9 rs2293581a, 
rs12708491a
1.07 1.05–1.10 1.4 × 10−10
 20p12.3 BMP2 rs28488 20 6,762,221 T/C 63.88 1.06 1.04–1.08 2.6 × 10−11 rs189583a, 
rs4813802a, 
rs994308
1.07 1.05–1.09 2.6 × 10−14
 20p12.3 BMP2 rs994308 20 6,603,622 C/T 59.39 1.08 1.06–1.10 4.8 × 10−18 rs189583a, 
rs4813802a, 
rs28488
1.06 1.05–1.08 8.6 × 10−12
Lead variant is the most associated variant at the locus in the conditional analysis. Reference SNP cluster ID (rsID) based on NCBI dbSNP Build 150. Alleles are on the +  strand. Chr., chromosome;  
RAF, risk allele frequency, based on stage 2 data; OR, odds ratio estimates are for the risk allele. Conditioning variants are the lead variant of other conditionally independent association signals with 
P < 1 ×  10−5 within 1 Mb of the new association signal. Because of extensive LD, we used a 2-Mb distance for the MHC region (6p21.32). All lead variants for the new association signals are in linkage 
equilibrium with any previously reported CRC risk variants at the locus (r2 <  0.10). aConditioning variant is either the index variant, or a variant in LD with the index variant reported in previous GWAS. 
Details and full results are in Supplementary Table 5.
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with at least one SNP in the NHGRI-EBI GWAS Catalog46 that has 
significant association in GWASs of other traits. Notable overlap 
included SNPs associated with other cancers, immune-related traits 
(for example, tonsillectomy, inflammatory bowel disease and cir-
culating white blood cell traits), obesity traits, blood pressure and 
other cardiometabolic traits (Supplementary Table 6).
Mechanisms underlying CRC association signals. To further 
localize variants driving the 40 newly identified signals, we used 
association evidence to define credible sets of variants that are 99% 
probable to contain the causal variant (Methods). The 99% credible 
set size for new loci ranged from one (17p12) to 93 (2q33.1). For 
11 distinct association signals, the set included ten or fewer vari-
ants (Supplementary Table 7). At locus 17p12, we narrowed the 
candidate variant to rs1078643, located in exon 1 of the lncRNA 
LINC00675, which is primarily expressed in gastrointestinal tissues. 
Small credible sets were observed for locus 4q31.21 (two variants, 
indexed by synonymous SNP rs11727676 in HHIP), and signals at 
known loci near GREM1 (one variant) and CCND2 (two variants).
We performed functional annotation of credible set variants 
to nominate putative causal variants. Eight sets contained cod-
ing variants, but only the synonymous SNP in HHIP had a high 
posterior probability of driving the association (Supplementary 
Table 8). Next, we examined overlap of credible sets with regula-
tory genomic annotations from 51 existing CRC-relevant data sets 
to examine noncoding functions (Methods). Also, to better refine 
regulatory elements in active enhancers, we performed the assay for 
transposase-accessible chromatin using sequencing (ATAC-seq) to 
measure chromatin accessibility in four colonic crypts and used the 
resulting data to annotate GWAS signals.
Of the 40 sets, 36 overlapped with active enhancers identified 
by histone mark H3K27ac, which was measured in normal colonic 
crypt epithelium, CRC cell lines or CRC tissue (Supplementary 
Table 8 and Supplementary Fig. 6). Twenty of these 36 sets over-
lapped with super-enhancers. Notably, when compared with epig-
enomics data from normal colonic crypt epithelium, all 36 sets 
overlapped with enhancers that gained or lost activity in one or 
more CRC specimens. Eleven of these sets overlapped with enhanc-
ers that recurrently gained or lost activity in ≥ 20 CRC cell lines.
The locus at GWAS hotspot 9p21 overlaps with a super-
enhancer, and the credible set is entirely intronic to ANRIL, alias 
CDKN2B-AS1. The Genotype-Tissue Expression (GTEx) data show 
that the antisense lncRNA ANRIL is exclusively expressed in trans-
verse colon and small intestine. Notably, ANRIL recruits SUZ12 and 
EHZ2 to epigenetically silence tumor suppressor genes CDKN2A 
and CDKN2B71.
Noncoding somatic driver mutations or focal amplifications have 
been reported in regions regulating expression of MYC72, TERT73 
and KLF5 (ref. 31), which are now implicated by GWAS for CRC. We 
checked whether GWAS-identified association signals colocalize 
with these regions and found that the KLF5 signal overlaps with the 
somatically amplified super-enhancer flanked by KLF5 and KLF12 
(Fig. 2). Also, the previously reported signal in the TERT promoter 
region22 overlaps with the recurrent somatically mutated region in 
multiple cancers73.
To test whether CRC associations are nonrandomly distrib-
uted across genomic features, we used GARFIELD74. Focusing on 
DNase I hypersensitive site peaks that identify open chromatin, we 
observed significant enrichment across many cell types, particularly 
fetal tissues, with the strongest enrichment observed in fetal gastro-
intestinal tissues, CD20+ primary cells (B cells) and embryonic stem 
cells (Supplementary Fig. 7 and Supplementary Table 9).
We used MAGENTA75 to identify pathways or gene sets enriched 
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Fig. 1 | conditionally independent association signals at the BMP2 locus. Regional association plot showing the unconditional –log10[P] for the association 
with CRC risk in the combined meta-analysis of up to 125,478 individuals, as a function of genomic position (build 37) for each variant in the chromosome 
20 (chr20) region. The lead variants are indicated by a diamond symbol, and their positions are indicated by dashed vertical lines. The color labeling  
and shape of all other variants indicate the lead variant with which they are in strongest LD. The two new genome-wide significant signals are indicated  
by asterisks.
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95th and 75th percentiles. At the 75th percentile, we observed 
enrichment of multiple KEGG cancer pathways at a false discovery 
rate (FDR) of 0.05. This was not observed for the 95th percentile 
cutoff and suggests that many more loci that are shared with other 
cancer types remain to be identified in larger studies. Using the 75th 
(95th) percentile cutoff, at FDR 0.05 and 0.20, we found enrichment 
of 7 (5) and 53 (24) gene sets, respectively. Established pathways 
related to TGF-β /SMAD and BMP signaling were among the top 
enriched pathways. Other notable enriched pathways included 
Hedgehog signaling, basal cell carcinoma, melanogenesis, cell cycle, 
S phase and telomere maintenance (Supplementary Table 10).
Polygenicity of CRC and contribution of rare variants. To estimate 
the contribution of rare variants (MAF ≤ 1%) to CRC heritability, 
we used the LD- and MAF-stratified component GREML (GREML-
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Fig. 2 | Functional genomic annotation of new cRc risk locus overlapping with KLF5 super-enhancer. Top, regional association plot showing the 
unconditional –log10[P] for the association with CRC risk in the combined meta-analysis of up to 125,478 individuals, as a function of genomic position 
(build 37) for each variant in the chromosome 13 (chr13) region. Lead variants are indicated by diamonds and their positions are indicated by dashed 
vertical lines. The color labeling and shape of all other variants indicate the lead variant with which they are in strongest LD. Bottom, UCSC genome 
browser annotations for region overlapping with the super-enhancer flanked by KLF5 and KLF12, spanning variants in LD with rs78341008, and with two 
conditionally independent association signals indexed by rs45597035 and rs1924816. The region is annotated with the following tracks (top to bottom): 
UCSC gene annotations; epigenomic profiles showing MACS2 peak calls as transparent overlays for different samples taken from nondiseased colonic 
crypt cells (NormalCrypt) or colon mucosa tissue (NormalMucosa) (purple) and from different primary CRC cell lines or tumor samples (teal); position of 
the lead variants and variants in LD with the lead; variants in the 99% credible set; the union of super-enhancers called using the ROSE package; targeted 
enhancers (e1, e3 and e4) shown by Zhang et al.31 to have combinatorial effects on KLF5 expression (gray bars). ATAC-seq data newly generated for this 
study show high-resolution annotation of putative binding regions within the active super-enhancer, further fine-mapping putative causal variants at each 
of the three signals. Dhs: DNase I hypersensitive sites.
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lifetime risk of 4.3%, we estimated that all imputed autosomal vari-
ants explain 21.6% (95% CI = 17.5–25.7%) of the variation in liabil-
ity for CRC, with almost half of this contributed by rare variants 
(hg
2 = 9.7%, 95% CI = 6.2–13.3%; likelihood ratio test P = 0.003); the 
estimated liability-scale heritability for variants with MAF > 1% is 
11.8% (95% CI = 8.9–14.7%). Our overall estimate falls within the 
range of heritability reported by large twin studies2. Because herita-
bility estimates for rare variants are sensitive to potential biases due 
to technical effects or population stratification77, and the contribu-
tion of rare variants is probably underestimated due to limitations of 
genotype imputation, the results should be interpreted with caution. 
Overall, the findings suggest that missing heritability is not large, 
but that many rare and common variants have yet to be identified.
Familial relative risk explained by GWAS-identified variants. 
Adjusting for the winner’s curse78, the familial relative risk (RR) 
to first-degree relatives (λ0) attributable to GWAS-identified vari-
ants rose from 1.072 for the 55 previously described autosomal 
risk variants that showed evidence for replication at P < 0.05, to 
1.092 after inclusion of 40 new signals, and increased further to 
1.098 when we included 25 suggestive association signals reported 
in Supplementary Table 5 (Methods). Assuming a λ0 of 2.2, the 55 
established signals account for 8.8% of familial RR explained (95% 
CI = 8.1–9.4). Established signals combined with 40 newly discov-
ered signals account for 11.2% (95% CI = 10.5–12.0), and adding 
25 suggestive signals increases this to 11.9% (95% CI = 11.1–12.7).
Implications for stratified screening prevention. We demonstrate 
how using a polygenic risk score (PRS) derived from 95 indepen-
dent association signals could affect clinical guidelines for pre-
ventive screening. The difference in recommended starting age 
for screening for those in the highest 1% (and 10%) percentiles of 
risk compared with lowest percentiles is 18 years (and 10 years) 
for men, and 24 years (and 12 years) for women (Fig. 3; Methods). 
Supplementary Table 11 gives risk allele frequency estimates in dif-
ferent populations for variants included in the PRS. As expected, risk 
allele frequencies vary across populations. Furthermore, differences 
in LD between tagging and true causal variants across populations 
can lead to less prediction accuracy and subsequent lower predictive 
power of the PRS in non-European populations. Accordingly, it will 
be important to develop ancestry-specific PRSs that incorporate 
detailed fine-mapping results for each GWAS signal.
Discussion
To further define the genetic architecture of sporadic CRC, we 
performed low-coverage WGS and imputation into a large set of 
GWAS data. We discovered 40 new CRC signals and replicated 55 
previously reported signals. We found the first rare variant signal 
for sporadic CRC, which represents the strongest protective rare 
allelic effect identified so far. Our analyses highlight new genes and 
pathways contributing to underlying CRC risk and suggest roles 
for Krüppel-like factors, Hedgehog signaling, Hippo-YAP signal-
ing and immune function. Multiple loci provide new evidence for 
an important role of lncRNAs in CRC tumorigenesis79. Functional 
genomic annotations support that most of the sporadic CRC genetic 
risk lies in noncoding genomic regions. We further show how newly 
discovered variants can lead to improved risk prediction.
This study underscores the critical importance of large-scale 
GWAS collaboration. Although discovery of the rare variant sig-
nal was possible only through increased coverage and improved 
imputation accuracy enabled by imputation panels, sample size 
was pivotal for discovery of new CRC loci. The results suggest 
that CRC has a highly polygenic architecture, much of which 
remains undefined. This also suggests that continued GWAS 
efforts, together with increasingly comprehensive imputation 
panels that allow for improved low-frequency and rare genetic 
variant imputation, will uncover more CRC risk variants. In addi-
tion, to investigate sites that are not imputable, large-scale deep 
sequencing will be needed. Importantly, the prevailing European 
bias in CRC GWASs limits the generalizability of findings and the 
application of PRSs in non-European (especially African) popula-
tions80. Therefore, a broader representation of ancestries in CRC 
GWASs is necessary.
Studies of somatic genomic alterations in cancer have mostly 
focused on the coding genome, and identification of noncoding 
drivers has been challenging73. Yet, noncoding somatic driver muta-
tions or focal amplifications in regulatory regions affecting expres-
sion have been reported for MYC72, TERT73 and KLF5 (ref. 31). The 
observed overlap between GWAS-identified CRC risk loci and 
somatic driver regions strongly suggests that expanding the search 
of somatic driver mutations to noncoding regulatory elements will 
yield additional discoveries and that searches for somatic drivers 
can be guided by GWAS findings.
Additionally, we found loci near proposed drug targets, includ-
ing CHD1, which is implicated by the rare variant signal, and KLF5. 
So far, cancer drug target discovery research has almost exclusively 
focused on properties of cancer cells, yielding drugs targeting 
proteins that are either highly expressed or expressed in a mutant 
form due to frequent recurrent somatic missense mutations (for 
example, BRAF p.Val600Glu) or gene fusion events. In stark con-
trast with other common complex diseases, cancer GWAS results 
are not being used extensively to inform drug target selection. It 
has been estimated that selecting targets supported by GWAS could 
double the success rate in clinical development81. Our discoveries 
corroborate that GWAS results can considerably inform drug dis-
covery, not only for treating cancers but also for chemoprevention 
in high-risk individuals.
In summary, in the largest genome-wide scan for sporadic CRC 
risk thus far, we identified the first rare variant signal for sporadic 
CRC, and almost doubled the number of known association signals. 
Our findings provide a substantial number of new leads that may 
spur downstream investigation into the biology of CRC risk, and 
that will influence drug development and clinical guidelines, such 
as personalized screening decisions.
URLs. EPACTS, https://genome.sph.umich.edu/wiki/EPACTS; 
ENCODE data processing pipeline, https://github.com/kundajelab/
atac_dnase_pipelines; WashU Epigenome Browser, https://epigeno-
megateway.wustl.edu.




























Fig. 3 | Recommended age to start cRc screening based on a polygenic 
risk score. The PRS was constructed using the 95 known and newly 
discovered variants. The horizontal line represents the recommended 
age for first endoscopy for a person with average risk using the current 
screening guidelines for CRC. The risk threshold to determine the age 
for the first screening was set as the average of 10-year CRC risks for a 
50-year-old man (1.25%) and woman (0.68%) who have not previously 
received an endoscopy. Details are in Methods.
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Methods
Study samples. After quality control (QC), this study included WGS data for 1,439 
CRC cases and 720 controls from 5 studies, and GWAS array data for 58,131 CRC 
or advanced adenoma cases (3,674; 6.3% of cases), and 67,347 controls from 45 
studies from GECCO, CORECT and CCFR. The stage 1 meta-analysis comprised 
existing genotyping data from 30 studies that were included in previously 
published CRC GWASs13,18,22. After QC, the stage 1 meta-analysis included 34,869 
cases and 29,051 controls. Study participants were predominantly of European 
ancestry (31,843 cases and 26,783 controls; 91.7% of participants). Because the 
vast majority of known CRC risk variants are shared between Europeans and East 
Asians17, we included 3,026 cases and 2,268 controls of East Asian ancestry to 
increase power for discovery. The stage 2 meta-analysis comprised newly generated 
genotype data involving four genotyping projects and 22 studies. After QC, the 
stage 2 meta-analysis included 23,262 cases and 38,296 controls, which were all 
of European ancestry. Studies, sample selection and matching are described in 
Supplementary Note. Supplementary Table 1 provides details on sample numbers 
and demographic characteristics of study participants. All participants provided 
written informed consent, and each study was approved by the relevant research 
ethics committee or institutional review board. Four normal colon mucosa biopsies 
for ATAC-seq were obtained from patients with a normal colon at colonoscopy at 
the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Spain. Patients signed 
informed consent, and the protocol was approved by the Bellvitge Hospital Ethics 
Committee (Colscreen protocol PR084/16).
Whole-genome sequencing. We performed low-pass WGS of 2,192 samples from 
five studies at the University of Washington Northwest Genomics Center (Seattle, 
WA, USA). Cases and controls were processed and sequenced together. Libraries 
were prepared with ThruPLEX DNA-seq kits (Rubicon Genomics) and paired-end 
sequencing was performed using Illumina HiSeq 2500 sequencers. Reads were 
mapped to human reference genome (GRCh37 assembly) using Burrows-Wheeler 
aligner BWA v0.6.2 (ref. 82). Fold genomic coverage averaged 5.3× (range: 3.8–8.6× ). 
We used the GotCloud population-based multisample variant calling pipeline83 
for post-processing of BAM files with initial alignments, and to detect and call 
single-nucleotide variants and short indels. After removing duplicated reads and 
recalibrating base quality scores, QC checks included sample contamination 
detection. Variants were jointly called across all samples. To identify high-quality 
sites, the GotCloud pipeline performs a two-step filtering process. First, lower 
quality variants are identified by applying individual variant quality statistic 
filters. Next, variants failing multiple filters are used as negative examples to train 
a support vector machine classifier. Finally, we performed a haplotype-aware 
genotype refinement step via Beagle84 and ThunderVCF85 on the support vector 
machine–filtered VCF files. After further sample QC, we excluded samples with 
estimated DNA contamination > 3% (n = 16), duplicated samples (n = 5) or related 
individuals (n = 1), sex discrepancies (n = 0), and samples with low concordance 
with GWAS array data (n = 11). We checked for ancestry outliers by performing 
principal component analysis (PCA) after merging in data for shared, LD-pruned 
single-nucleotide variants for 1,092 individuals from the 1000 Genomes Project86. 
After QC, sequences were available for 1,439 CRC cases and 720 controls of 
European ancestry.
GWAS genotype data and quality control. Details of genotyping and QC for 
studies included in the stage 1 meta-analysis are described elsewhere13,18,22. 
Supplementary Table 1 provides details of genotyping platforms used. Before 
association analysis, we pooled individual-level genotype data of all stage 1 studies 
for a subset of SNPs to enable identification of unexpected duplicates and close 
relatives. We calculated identity by descent for each pair of samples using KING-
robust87 and excluded duplicates and individuals that were second-degree or more 
closely related. As part of stage 2, 28,805 individuals from 19 studies were newly 
genotyped on a custom Illumina array based on the Infinium OncoArray-500K26 
and a panel of 15,802 successfully manufactured custom variants (described in 
Supplementary Note). An additional 8,725 individuals from five studies were 
genotyped on the Illumina HumanOmniExpressExome-8v1-2 array. Genotyping 
and calling for both projects were performed at the Center for Inherited Disease 
Research (CIDR) at Johns Hopkins University. Genotypic data that passed initial 
QC at CIDR subsequently underwent QC at the University of Washington 
Genetic Analysis Center (UW GAC) using standardized methods detailed in 
Laurie et al.88. The median call rate for the custom Infinium OncoArray-500K 
data was 99.97%, and error rate estimated from 301 sample duplicate pairs was 
9.99 × 10−7. A relatively low number of samples (n = 246) had a missing call 
rate > 2%, with the highest being 3.48%, and were included in analysis. For the 
HumanOmniExpressExome-8v1-2 data, median call rate was 99.96%, and the 
error rate estimated from 179 sample duplicate pairs was 2.65 × 10−6. Some 30 
samples had a missing call rate > 2%, with the highest being 3.79%, and were 
included in analysis. We excluded samples with discrepancies between reported 
and genotypic sex based on X chromosome heterozygosity and the mean values 
of sex chromosome probe intensities, unintentional duplicates, and close relatives, 
defined as individuals that are second-degree or more closely related. After further 
excluding individuals of non-European ancestry as determined by PCA (see 
below), the custom OncoArray data included in analysis comprised 11,852 CRC 
cases and 11,895 controls, and the HumanOmniExpressExome-8v1-2 array data 
included in analysis comprised 4,439 CRC cases and 4,115 controls. Only variants 
passing QC were used for imputation. We excluded variants failing CIDR technical 
filters or UW GAC quality filters, which included missing call rate > 2%, discordant 
calls in sample duplicates, and departures from Hardy-Weinberg equilibrium 
(HWE) (P < 1 × 10−4) based on European-ancestry controls. The stage 2 analysis 
also included genotype data from the CORSA study (Supplementary Note). In 
total, 2,354 individuals were genotyped using the Affymetrix Axiom Genome-
Wide Human CEU 1 Array. We called genotypes using the AxiomGT1 algorithm. 
All samples had missing call rate < 3%. We excluded samples with discrepancies 
between reported and genotypic sex (n = 20), close relatives, defined as individuals 
that are second-degree or more closely related (n = 94), as inferred using KING-
robust87, and individuals of non-European ancestry (n = 6) as inferred from PCA. 
After QC, data included in analysis comprised 1,460 cases and 774 controls. 
Before phasing and imputation, we filtered out SNPs with missing call rate > 2%, 
or HWE P < 1 × 10−4. Imputed genotype data were obtained from UK Biobank and 
QC and imputation are described elsewhere89. A nested case-control data set was 
constructed as described in Supplementary Note. We excluded individuals of non-
European ancestry as inferred from PCA, and randomly dropped one individual 
from each pair that were more closely related than third-degree relatives as inferred 
using KING-robust. This led to excluding 137 samples. In total, 5,356 CRC 
(n = 5,004) or advanced adenoma (n = 352) cases and 21,407 matched controls were 
included in the replication analysis.
Principal component analysis. After excluding close relatives, we performed 
PCA using PLINK1.9 (ref. 90) on LD-pruned sets of autosomal SNPs obtained by 
removing regions with extensive long-range LD91,92, SNPs with MAF < 5%, HWE 
P < 1 × 10−4, or any genotype missingness, and carrying out LD pruning using 
the PLINK option “-indep-pairwise 50 5 0.2.” To identify population outliers we 
merged in 1,092 individuals from 1000 Genomes Project Phase III and performed 
PCA using the intersection of variants93.
Genotype imputation. The 2,159 whole-genome sequences described above were 
used to create a phased imputation reference panel. After estimating haplotypes  
for all GWAS array data sets using SHAPEIT2 (ref. 94), we used minimac3 (ref. 95)  
to impute from this reference panel (19.6 million variants with MAC > 1) into the 
GWAS data sets described above. We also imputed to the Haplotype Reference 
Consortium (HRC) panel25 (39.2 million variants) using the University of 
Michigan Imputation Server95. To improve imputation accuracy for stage 1 data 
sets, phasing and imputation were performed after pooling studies or genotyping 
projects that used the same, or very similar, genotyping platforms (Supplementary 
Table 1). For stage 2, we performed phasing and imputation separately for each 
genotyping project data set and imputed to the HCR panel.
Statistical analyses. Association testing of sequence data. We tested variants with 
MAC ≥ 5 for CRC association using Firth’s bias-reduced logistic regression as 
implemented in EPACTS (see URLs) and adjusted for sex, age, study and three 
principal components calculated from an LD-pruned set of genotypes. We 
performed rare variant aggregate tests at the gene and enhancer level using the 
Mixed effects Score Test (MiST)96. This unified test is a linear combination between 
unidirectional burden and bidirectional variance component tests that performs 
best in terms of statistical power across a range of architectures97.
Association and meta-analysis. Stage 1 comprised two large mega-analyses of 
pooled individual-level genotype data sets (Supplementary Table 12). The four 
stage-2 genotyping project data sets were analyzed separately. Within each data 
set, variants with an imputation accuracy r2 ≥ 0.3 and MAC ≥ 50 were tested for 
CRC association using the imputed genotype dosage in a logistic regression model 
adjusted for age, sex and study or genotyping project–specific covariates, including 
principal components to adjust for population structure (Supplementary Table 12). 
To account for residual confounding within CORSA, we tested association with 
each variant using a linear mixed model and kinship matrix calculated from the 
data, as implemented in EMMAX98. To enable meta-analysis, we then calculated 
approximate allelic log[OR] estimates and corresponding standard errors as 
described in Cook et al.99.
Next, we combined association summary statistics across analyses via fixed-
effects inverse variance–weighted meta-analysis. Because Wald tests can be notably 
anti-conservative for rare variant associations, we also performed likelihood 
ratio-based tests, followed by sample-size weighted meta-analysis, as implemented 
in METAL100. In total, 16,900,397 variants were analyzed. To examine residual 
population stratification, we inspected quantile-quantile plots of test statistics 
(Supplementary Fig. 8) and calculated genomic control inflation statistics (λGC). 
λGC for the combined meta-analysis was 1.105, and for stage 1 and stage 2 meta-
analyses was 1.071 and 1.075, respectively. Because λGC increases with sample 
size for polygenic phenotypes, even in the absence of confounding biases101, we 
investigated the effect of confounding due to residual population stratification 
using LD score regression102. Because of limitations of LD score regression, this 
analysis is restricted to common variants (MAF ≥ 1%) for which λGC was 1.188 in 
the combined meta-analysis. The LD score regression intercept was 1.067, which is 
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substantially less than λGC, indicating at most a small contribution of bias and that 
inflation in χ2 statistics results mostly from polygenicity. We also calculated λ1,000, 
which is the equivalent inflation statistic for a study with 1,000 cases and 1,000 
controls103. For the combined meta-analysis, λ1000 was 1.004 and for both stage 1 
and stage 2 meta-analyses it was 1.003.
Significance threshold for the replication genotyping experiment. To protect against 
probe design failure, we built redundancy into the custom genotyping panel by 
including LD proxies of independently associated variants selected for follow-up. 
To determine the number of independent tests, we performed LD clumping of 
the 9,198 analyzed variants that were selected for replication genotyping based 
on the stage 1 meta-analysis, and that survived filters described above. Using an 
r2 threshold of 0.1 this translated to 6,438 independent tests and a Bonferroni 
significance threshold of 0.05/6,438 = 7.8 × 10−6.
Conditional and joint multiple-variant analysis. To identify additional distinct 
association signals at CRC loci, we performed a series of conditional meta-
analyses. At each locus attaining P < 5 × 10−8, we included the genotype dosage for 
the variant showing the strongest statistical evidence for association in the region 
in the combined meta-analysis, as an additional covariate in the respective logistic 
regression models. Association summary statistics for each variant in the region 
were then combined across studies by a fixed-effects meta-analysis. If at least one 
association signal attained a significance level of P < 1 × 10−5 in this meta-analysis, 
we performed a second round of conditional meta-analysis, adding the variant 
showing the strongest statistical evidence for association in the region in the first 
round of conditional meta-analysis as a covariate to the logistic regression models 
used in the first round. We repeated this procedure and kept adding variants to 
the model until no additional variants at the locus attained P < 1 × 10−5. Finally, 
we performed a joint multiple-variant analysis in which we jointly estimated the 
effects of variants selected in each step and tested for each variant whether the  
P value from the joint multiple-variant analysis (PJ) was < 1 × 10−5. Analyses were 
performed on 2-Mb windows centered on the most associated variant in the 
unconditional analysis. If windows overlapped, we performed the analysis on the 
collapsed genomic region. Because of extensive LD, we used a 4-Mb window for 
the MHC region.
Definition of known loci. We compiled a list of 62 previously reported genome-
wide significant CRC association signals from the literature (Supplementary  
Table 3). Because of improved power and coverage of our study, we identified the 
most associated variant at each signal, and used these lead variants for further 
analyses, rather than the previously reported index variant.
Refinement of association signals. To refine new association signals, we 
constructed credible sets that were 99% probable, based on posterior probability, 
to contain the causal disease-associated SNP104. In brief, for each distinct signal, 
we retained a candidate set of variants by identifying all analyzed variants with 
r2 ≥ 0.1 with the most associated variant within a 2-Mb window centered on the 
most associated variant. We calculated approximate Bayes’ factors (ABFs)105 for 
each variant as:
= − ∕ABF r e1 rz 2
2
where r = 0.04/(s.e.2 + 0.04), z = β/s.e., and β and s.e. are the log[OR] estimate 
and its standard error from the combined meta-analysis, respectively. For loci 
with multiple distinct signals, results are based on conditional meta-analysis, 
adjusting for all other index variants in the region. We then calculated the posterior 
probability of being causal as ABF/T where T is the sum of ABF values over all 
candidate variants. Next, variants were ranked in decreasing order by posterior 
probabilities and the 99% credible set was obtained by including variants with the 
highest posterior probabilities until the cumulative posterior probability was ≥ 99%.
Functional genomic annotation. To nominate variants for future laboratory 
follow-up, we performed bioinformatic analysis at each new signal using our 
functional annotation database, and a custom University of California Santa Cruz 
(UCSC) analysis data hub. Using ANNOVAR106, we annotated lead variants and 
variants in LD (r2 ≥ 0.4) with the lead variant, relative to features pertaining to: 
(1) gene-centric function (PolyPhen2107); (2) genome-wide functional prediction 
scores (CADD108, DANN109 and EigenPC110); (3) disease relatedness (GWAS 
catalog46) and (4) CRC-relevant regulatory functions (enhancer, repressor, 
DNA accessible and transcription factor–binding site111,112; Supplementary 
Table 13). Supplementary Table 8 summarizes variant annotations relative to 
the Consensus Coding Sequence (CCDS) Project113, and reference genome 
GRCh37. Variants were maintained in Supplementary Table 8 if they met any 
of the following conditions: DANN score ≥ 0.9, CADD phred score ≥ 20, Eigen-
PC phred score ≥ 17, PolyPhen2 prediction of “probably damaging,” stop-loss, 
stop-gain, or splicing variant, or positioned in a predicted regulatory element. 
We visually inspected loci overlapping with CRC-relevant functional genomic 
annotations. Variants positioned in enhancers with aberrant CRC activity were 
identified by comparing epigenomes of nondiseased colorectal tissues or colonic 
crypt cells to epigenomes of primary CRC cell lines. We prioritized target genes 
for loci with predicted regulatory function. Evidence suggests that topological 
association domains can be used to map physical boundaries on gene promoter 
interactions with distal regulatory elements114–116. As such, we used GM12878 Hi-C 
Chromosome Conformation Capture data to identify gene promoters that were in 
the same topological association domains as risk loci using the WashU Epigenome 
Browser (see URLs). Genes in this list were further prioritized based on biological 
relevance and expression quantitative trait loci data from GTEx117 using HaploReg 
v4.1 (ref. 118).
Assay for transposable-accessible chromatin using sequencing. We generated 
high-resolution maps of DNA-accessible regions in normal colon mucosa samples 
using ATAC-seq. Using the updated omni-ATAC protocol for archival samples, 
we performed ATAC-seq in four colon mucosa biopsies from the Catalan Institute 
of Oncology (ICO)-biobank taken from participants undergoing screening at 
IDIBELL, Spain. Biopsies were cryopreserved by slow freezing using a solution 
of 10% dimethylsulfoxide, 90% medium and Mr. Frosty Cryo 1 °C Freezing 
Containers (Thermo Scientific). ATAC-seq was implemented as prescribed 
with two exceptions. Instead of Dounce homogenizer, we used a tissue lyser and 
stainless bead system, pulverizing at 40 Hz for 2 min and pulsing at 50 Hz for 
10–20 s. Secondly, Illumina library quantification was performed using picogreen 
quantitation and TapeStation instead of KAPA quantitative PCR. Libraries were 
sequenced to an average of 25 million paired end reads using Illumina HiSeq 2500. 
The ENCODE data processing pipeline was implemented (see URLs) aligning to 
hg19 (ref. 119). QC results are summarized in Supplementary Table 14.
Regulatory and functional information enrichment analysis. We used 
GARFIELD74 to identify cell types, tissues and functional genomic features 
relevant to CRC risk. This method tests for enrichment of association in features 
primarily extracted from ENCODE and Roadmap Epigenomics Project data, while 
accounting for confounding variables, including LD. We applied default settings 
and used the author-supplied data, which are suitable for analysis of GWAS results 
based on individuals of European ancestry.
Pathway and gene set enrichment analysis. We used MAGENTA to test 
predefined gene sets (for example, KEGG pathways) for enrichment for CRC risk 
associations75. We used combined meta-analysis results as input and applied default 
settings, which included removing genes that fall in the MHC region from analysis. 
Enrichment was tested at two gene P-value cutoffs: the 95th and 75th percentiles of 
all gene P values in the genome.
Estimation of contribution of rare variants to heritability. We used the LD- and 
MAF-stratified component GREML (GREML-LDMS) method as implemented in 
GCTA76 to estimate the proportion of variation in liability for CRC explained by all 
imputed autosomal variants (that is, estimate of narrow-sense heritability hg
2), and 
the proportion contributed by rare variants (MAF ≤ 1%). Because of computational 
limitations we analyzed a subset of 11,895 cases and 14,659 controls imputed 
to our WGS panel. We analyzed individual-level data for 17,649,167 imputed 
variants with MAC > 3 and HWE test P ≥ 10−6. Following Yang et al.76, we did 
not filter based on imputation quality. In brief, we stratified variants into groups 
based on MAF (boundaries at 0.001, 0.01, 0.1, 0.2, 0.3 and 0.4) and mean LD score 
(boundaries at quartiles) calculated as described in Yang et al76. We then calculated 
genetic relationship matrices for each of these 28 variant partitions and jointly 
estimated variance components for these partitions, adjusting for age, sex, study, 
genotyping batch and three genotype prinicipal components. From the variance 
component estimates and their variance-covariance matrix we estimated the 
contribution of rare variants (MAF ≤ 1%) and common variants (MAF > 1%), and 
calculated standard errors using the delta method. We tested significance of the 
contribution of rare variants using a likelihood ratio test. To calculate heritability 
on the underlying liability scale we interpreted K as lifetime risk120 and used an 
estimate of 4.3% (Surveillance, Epidemiology, and End Results Program (SEER) 
Cancer Statistics, 2011–2013).
Familial relative risk explained by genetic variants. We assumed a multiplicative 
model within and between variants and calculated the proportion of familial RR 
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2, where pi is the risk allele frequency for variant i, qi = 1 – pi, and ri is 
the estimated per-allele OR9,121. We adjusted the OR estimates of new association 
signals for the winner’s curse following Zhong and Prentice78. We represented 
previously identified association signals by the variant showing the strongest 
statistical evidence of association in the combined meta-analysis, and assumed that 
the winner’s curse was negligible. We assumed λ0 to be 2.2 (ref. 122). Using the delta 



















( ) 1 1
2 ( 1)





NatuRe GeNetics | www.nature.com/naturegenetics
Articles Nature GeNetics
Absolute risk of CRC incidence and starting age of first screening. We 
constructed a PRS as a weighted sum of the number of risk alleles carried by an 
individual, using the per-allele OR for each variant as weights. OR estimates for 
newly discovered variants were adjusted for the winner’s curse to avoid potential 
inflation78. Assuming all genetic variants are independent, let X denote a PRS 
constructed based on K variants: β= ∑ ̂=X Zi
K
i i1 , where β
̂
i and Zi are the estimated 
OR and the number of risk alleles for variant i. We assumed X follows a normal 
distribution N(μ,σ2), where the estimates of mean and variance are computed as 
follows:
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and λ*(t) are the incidence rates for non-Hispanic whites who have not taken an 
endoscopy before, derived from population incidence rates during 1992–2005 from 
the SEER Registry. Using these baseline hazard rates, we estimated the 10-year 
absolute risk of developing CRC given age and a PRS as described123. By setting a 
risk threshold as the average of the 10-year CRC risk for a 50-year old man (1.25%) 
and woman (0.68%) who have not previously received an endoscopy124, that is, 
(1.25% + 0.68%)/2 = 0.97%, we estimated the recommended starting age of first 
screening given the PRS. Variants and OR estimates used in these analyses are in 
Supplementary Table 15.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All whole-genome sequence data have been deposited in the database of Genotypes 
and Phenotypes (dbGaP), which is hosted by NCBI, under accession number 
phs001554.v1.p1. All custom Infinium OncoArray-500K array data for the studies 
in the stage 2 meta-analysis have been deposited at dbGaP under accession number 
phs001415.v1.p1. All Illumina HumanOmniExpressExome-8v1-2 array data for the 
studies in the stage 2 meta-analysis have been deposited at dbGaP under accession 
number phs001315.v1.p1. Genotype data for the studies included in the stage 1 
meta-analysis have been deposited at dbGaP under accession number phs001078.
v1.p1. The UK Biobank resource was accessed through application number 8614. 
CRC-relevant epigenome data were obtained from the NCBI Gene Expression 
Omnibus (GEO) database under accession number GSE77737.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection No software was used to collect data.
Data analysis Genotype calling for new genotyping projects was performed using Illumina's GenomeStudio version 2011.1, Genotyping Module v1.9.4, 
GenTrain v 1.0 algorithm, and Affymetrix Power Tools version 1.18.2 and the AxiomGT1 algorithm. Alignment of whole-genome sequence 
reads was performed using BWA v0.6.2 and variant calling using the GotCloud pipeline, which uses Beagle and ThunderVCF. Software 
used for genotyping quality control included PLINK1.9, KING 2.0.9, and the R package GWASTools. Phasing and imputation were 
performed using SHAPEIT2 and minimac3, respectively. Imputation to the Haplotype Reference Consortium panel was performed using 
the University of Michigan Imputation Server. Association analyses were performed using R, EPACTS v3.3.0, and METAL. Variant 
annotation was performed using ANNOVAR. Gene prioritization was performed using HaploReg v4.1. Functional and pathway enrichment 
analyses were conducted using GARFIELD v2 and MAGENTA v2. ATAC-Seq peak calling was performed using the ENCODE pipeline. 
Heritability analyses were performed using the GCTA package version 1.25.2. LD score regression was performed using ldsc version 1.0.0. 
The familial relative risk explained and risk prediction calculations were performed using R.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All whole-genome sequence data have been deposited at the database of Genotypes and Phenotypes (dbGaP), which is hosted by the U.S. National Center for 
Biotechnology Information (NCBI), under accession number phs001554.v1.p1. All custom Infinium OncoArray-500K array data for the studies in the Stage 2 meta-
analysis have been deposited at dbGaP under accession number phs001415.v1.p1. All Illumina HumanOmniExpressExome-8v1-2 array data for the studies in the 
Stage 2 meta-analysis have been deposited at dbGaP under accession number phs001315.v1.p1. Genotype data for the studies included in the Stage 1 meta-
analysis have been deposited at dbGaP under accession number phs001078.v1.p1. The UK Biobank resource was accessed through application number 8614.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size This work used newly generated whole-genome sequencing data (WGS; n=2,159), and existing and newly generated GWAS data on colorectal 
cancer (CRC; total n=125,478). Both datasets comprise the largest and most comprehensive to date. Rationale for the WGS study design 
which balanced sample size and sequencing coverage, is detailed under Study Overview in the Results section of the article. No sample size 
calculations were performed for the GWAS meta-analysis. We attempted to include as many studies as possible in the meta-analysis to 
maximize statistical power for discovery. Given that we almost doubled the sample size compared to the previous largest CRC GWAS meta-
analysis, and the improved and more comprehensive genotype imputation, we expected to have substantially higher statistical power to 
detect variants with smaller effect sizes or low minor allele frequencies.
Data exclusions We excluded samples and variants, using standardized methods and predefined filtering criteria to remove unreliable genotype calls or 
problematic samples, as described in the Online Methods. Sample exclusions included samples with evidence of DNA contamination, samples 
with high missing genotype rates, unintentional duplicate pairs, sex discrepancies, and closely related individuals. To avoid confounding due to 
population stratification, we excluded ancestry outliers identified through principal components analysis. Variants were excluded according to 
predefined quality controls filtering criteria as detailed in the Online Methods. For the WGS dataset this involved quality filtering based on a 
support vector machine (SVM) classifier; for the genotype array data, this included missing call rate filters, Hardy-Weinberg equilibrium, and 
various technical filters. Imputed genotype data were filtered on imputation quality and minor allele count.
Replication We present two sets of results: 1) new association signals for CRC risk that replicate (i.e., attain a Bonferroni significance threshold) in our 
independent custom replication genotyping experiment, and 2) new association signals for CRC risk based on all available data. Since 2) is 
based on the largest CRC GWAS dataset (>125,000 individuals), a well-powered replication dataset is currently not available.
Randomization To limit potentially confounding experimental batch effects, we sequenced and genotyped cases and controls together and randomized 
samples across flow cells or plates. Likewise, variant calling, phasing and imputation were performed for cases and controls together. Since 
this is an observational genetic association study, randomization to experimental groups is not relevant.
Blinding The laboratories conducting the sequencing or genotyping did not have access to phenotype data. Genotype calling was also blinded with 
respect to case-control status.
Reporting for specific materials, systems and methods
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Policy information about studies involving human research participants
Population characteristics Participants were adult colorectal cancer (CRC) or advanced adenoma patients, or healthy controls. The composition of the study 
in terms of sex and age reflects the underlying study populations and demographic characteristics for each participating study 
are summarized in Supplementary Table 1.
Recruitment This is an observational case control GWAS study for CRC. Details of participant enrollment, selection of matching healthy 
controls, and inclusion and exclusion criteria vary between studies and are described in the Supplementary Text for each of the 
45 studies (for newly generated data), or references are given in the Online Methods (for published data). In brief, all CRC or 
advanced adenoma cases were histologically or clinically confirmed, and controls with a known history of cancer or reported 
family history of CRC were excluded.
